Israeli medical device company Mazor Robotics Ltd. (TASE: MZOR) (Nasdaq: MZOR) announced today that it had received 11 orders for its Renaissance system in the second quarter of 2016. As a result, the company's share price rose 10.5% on the Tel Aviv Stock Exchange TASE)
The company reports having received orders for six systems in the US, including two systems with brain modules and five orders from distribution partners elsewhere, three of which are from China, one from Italy and one from Australia.
The company reports that one of the three systems in China was delivered to the Chinese distribution partner and the two others will be delivered during the second half of 2016.
“The continued interest in the Renaissance system and the solid execution of our growth strategies reaffirm my view that 2016 will be a year of significant growth for Mazor,” said Mazor CEO Ori Hadomi.
Hadomi added, “We received purchase orders for eleven Renaissance systems during the second quarter the second highest amount in our history. I remain encouraged about our prospects in China and reaffirm our long-term positive view on the market opportunity for Renaissance in this fast growing market.”
Mazor Robotics ended the second quarter with 122 Renaissance systems sold globally, including 74 in the US, the company’s primary growth market. In January 2016, Mazor Robotics reported a record number of 12 system orders during the fourth quarter, which ended in 31 December 2015.
Published by Globes [online], Israel business news - www.globes-online.com - on July 6, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016